Actelion Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd

Dorte Renneberg

Francis Hubler

Kurt Hilpert

Simon Stamm

Eva Caroff

Emmanuel Meyer

Thierry Kimmerlin

Mark Murphy

Sylvie Froidevaux

David Lehmann

Markus Von Raumer

Stefan Abele

Jacques-Alexis Funel

Katharina Reichenbaecher

Stéphanie Combes

Oliver Geiseler

Amandine Fraichard

Charlyse Herrmann

Michael Ambuehl

Elvire Fournier

Stephanie Combes

The present invention relates to derivatives of formula (I) wherein ring A, X, Y, Z, R, R, Rand Rare as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

C5A receptor modulators

The present invention relates to derivatives of formula (I) wherein Ring A, X, Y, Z, R, R, R, Rand Rare as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators

The invention relates to indole carboxamide derivatives of formula (I), wherein R, R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Indole carboxamide derivatives as P2X7 receptor antagonist

The invention relates to indole carboxamide derivatives of formula (I), wherein R, R, R, R, R, R, R, R, R, Rand n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

[object Object]

The invention relates to heterocyclic amide derivatives of formula (I), 

Heterocyclic amide derivatives as P2X7 receptor antagonists

The invention relates to heterocyclic amide derivatives of formula (I), wherein R, R, R, R, R, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.

The invention relates to heterocyclic amide derivatives of formula (I), wherein R, R, R, R, n and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.

The invention relates to heterocyclic amide derivatives of formula (I), wherein R, R, R, R, R, X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds. 

The present invention relates to thiazole derivatives of formula I and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. 

Thiazole derivatives and their use as P2Y12 receptor antagonists

The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I). 

The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-{[3-(4,7 -dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.

Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester

The invention relates to compounds of Formula (I) wherein R, R, R, R, R, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. 

Tetrahydronaphthalene compounds

The invention relates to compounds of formula (I) wherein R, R, R, R, A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. 

Bridged tetrahydronaphthalene derivatives

The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines

The invention relates to compounds of formula (I), wherein R, R, R, R, R, R, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. 

Growing community of inventors

Allschwil, Switzerland

Dorte Renneberg